4D Molecular Therapeutics (FDMT) Assets (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Assets of $512.9 million for Q1 2026, down 0.55% year-over-year from $515.7 million in Q1 2025, and down 9.49% quarter-over-quarter from $566.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Assets (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Assets for 8 consecutive years, with $512.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 0.55% year-over-year to $512.9 million; the TTM figure through Mar 2026 stood at $512.9 million (down 0.55% YoY), while the FY2025 annual figure was $566.7 million, up 1.13% from the prior year.
- Assets eased to $512.9 million in Q1 2026 per FDMT's latest filing, from $566.7 million in the prior quarter.
- Across five years, Assets topped out at $629.9 million in Q1 2024 and bottomed at $244.0 million in Q1 2023.
- Historically, Assets has averaged $433.8 million across 5 years, with a median of $424.0 million in 2025.
- Annual changes were most pronounced in 2024 — Assets soared 158.13% — and 2025, when it dropped 29.81%.
- 4D Molecular Therapeutics' Assets stood at $261.8 million in 2022, then grew by 29.81% to $339.9 million in 2023, then jumped by 64.87% to $560.4 million in 2024, then advanced by 1.13% to $566.7 million in 2025, then declined by 9.49% to $512.9 million in 2026.
- Business Quant data shows FDMT's Assets at $512.9 million in Q1 2026, $566.7 million in Q4 2025, and $424.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 492.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 492.62 Mn |
| Mar 31, 2026 | 512.91 Mn |
| Dec 31, 2025 | 566.71 Mn |
| Sep 30, 2025 | 423.98 Mn |
| Jun 30, 2025 | 473.64 Mn |
| Mar 31, 2025 | 515.73 Mn |
| Dec 31, 2024 | 560.38 Mn |
| Sep 30, 2024 | 604.03 Mn |
| Jun 30, 2024 | 620.12 Mn |
| Mar 31, 2024 | 629.88 Mn |
| Dec 31, 2023 | 339.89 Mn |
| Sep 30, 2023 | 361.61 Mn |
| Jun 30, 2023 | 352.50 Mn |
| Mar 31, 2023 | 244.02 Mn |
| Dec 31, 2022 | 261.85 Mn |
| Sep 30, 2022 | 280.16 Mn |
| Jun 30, 2022 | 302.94 Mn |
| Mar 31, 2022 | 324.93 Mn |
| Dec 31, 2021 | 353.49 Mn |
| Sep 30, 2021 | 240.62 Mn |